Aurinia Pharmaceuticals

Cara Therapeutics

Travere Therapeutics

Vera Therapeutics

Nephros, Inc.

Akebia Therapeutics

ProKidney Corp. Class A

Ardelyx Inc

Cadrenal Therapeutics, Inc.

Dilution score: 18/100 (LOW), 24.0 months cash

Short interest: 7.15% of float, squeeze risk: MODERATE

144 PubMed publications found for Aurinia

Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial.

Prediabetes in Children and Adults with Glomerular Disease.

Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex.

Evaluation of the Long-Term Safety of Avacopan in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in the Real World (AvacoStar): Protocol for a Noninterventional Prospective Cohort Study.

Measurement of haemolytic anaemia in a novel treatment response measure for SLE clinical trials.

Dilution score: 10/100 (LOW), 999.0 months cash

Short interest: 7.16% of float, squeeze risk: MODERATE

Short interest: 7.05% of float, squeeze risk: MODERATE

Short interest: 7.04% of float, squeeze risk: MODERATE

SW convergence: 55/100 (Neutral), 1 bullish / 0 bearish signals

SW convergence: 55/100 (Neutral), 2 bullish / 1 bearish signals

Short interest: 7.22% of float, squeeze risk: MODERATE

143 PubMed publications found for Aurinia

Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumab.

Short interest: 6.98% of float, squeeze risk: MODERATE

142 PubMed publications found for Aurinia

Voclosporin ameliorates proteinuria in a model of non-inflammatory glomerular disease.

141 PubMed publications found for Aurinia

Cost-Effectiveness of Early vs Delayed Belimumab Treatment for Systemic Lupus Erythematosus.

<article class="bts-verified-summary" data-ticker="AUPH">
<p>Aurinia Pharmaceuticals (AUPH) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.</p>
<p>No Form 4 insider filings for AUPH were recorded at the SEC in the past 30 days<sup><a href="#fn-1">[1]</a></sup>.</p>
<section class="sources"><h3>Sources</h3><ol><li id="fn-1">SEC EDGAR, 0001600620. Source last updated 2026-04-10, retrieved 2026-04-10. <a href="https://efts.sec.gov/LATEST/search-index?q=%22AUPH%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-11&amp;enddt=2026-04-10" rel="nofollow noopener">link</a></li></ol></section>
</article>

SEC EDGAR — 0001600620

Aurinia Pharmaceuticals (AUPH) — BioTechSigns Verified Summary

Aurinia Pharmaceuticals (AUPH) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.

No Form 4 insider filings for AUPH were recorded at the SEC in the past 30 days[1].

Sources:
[1] SEC EDGAR, 0001600620. Source last updated 2026-04-10, retrieved 2026-04-10.
    https://efts.sec.gov/LATEST/search-index?q=%22AUPH%22&forms=4&dateRange=custom&startdt=2026-03-11&enddt=2026-04-10